Clinical trials: Advanced Solid Tumors Harboring With G12C Mutation
Neoplasms, Advanced Solid Tumors
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JNJ-74699157 in participants with advanced solid tumors harboring a kirsten rat sarcoma virus homolog (KRAS)…
- Conditions
- Neoplasms, Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT04006301
- Testing
- JNJ-74699157
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumor, NSCLC
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.
- Conditions
- Advanced Solid Tumor, NSCLC, CRC
- Trial name
- NCT05002270
- Testing
- JAB-21822 (KRAS G12C inhibitor), Cetuximab (EGFR inhibitor)
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Non Small Cell Lung Cancer
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas
- Trial name
- NCT05485974
- Testing
- HBI-2438
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 44 people
- Sponsor
- HUYABIO International, LLC.
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
This is a FIH, ascending dose study to characterize the safety, tolerability, optimal dose and preliminary anti-tumor activity of IMM-6-415 in participants with advanced or metastatic solid tumors harboring RAS or RAF oncogenic…
- Conditions
- Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
- Trial name
- NCT06208124
- Testing
- IMM-6-415
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Immuneering Corporation
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C…
- Trial name
- NCT06435455
- Testing
- GH21, D-1553
- Volunteers
- 126 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined…
- Trial name
- KontRASt-R (NCT07468071)
- Testing
- Opnurasib, TNO155, trametinib
- Where
- 21 sites in Belgium, Canada and 8 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors Harboring KRAS G12C Mutation
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Researchers are looking for a better way to treat people who have advanced solid cancers with a KRASG12C mutation. Sotorasib is a drug that targets cancer cells which contain mutated KRASG12C protein; it can stop the cancer cells…
- Trial name
- NCT06659341
- Testing
- BAY3498264
- Where
- 11 sites in Australia, Denmark and 3 more
- Volunteers
- 104 people
- Sponsor
- Bayer
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06447662
- Testing
- PF-07934040, Gemcitabine, Nab-paclitaxel
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Pfizer
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This was Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
- Trial name
- KontRASt-03 (NCT05358249)
- Testing
- JDQ443, trametinib, Ribociclib
- Where
- 13 sites in United States, Belgium and 6 more
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid…
- Trial name
- NCT06959615
- Testing
- JAB-23E73
- Where
- 32 sites in China
- Volunteers
- 334 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Advanced Solid Tumors Harboring With G12C Mutation
GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results
Evaluate the safety and tolerability of GH35 in patients with KRAS mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in patients with KRAS mutant advanced solid…
- Trial name
- NCT05010694
- Testing
- GH35 Tablet
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.